Tel Aviv University’s TTO has set up a business called Nemis Technologies in partnership with BioSynth to develop pathological bacteria detection technologies powered by chemiluminescence.
Ramot, the tech transfer and business engagement arm of Tel Aviv University, joined forces with biochemicals supplier BioSynth today to launch Israel-based bacteria detection technology developer Nemis Technologies.
Nemis will leverage a pathogenic bacteria detection technology called AquaSpark co-developed by Ramot and Biosynth to build diagnostic kits that could be used to prevent contamination in food production, water treatment and clinical settings.
The technology is a response to fears over the growing number of food-borne illnesses and antibiotic resistance.
Nemis’s platform is powered by chemiluminescent probes that reveal potentially fatal bacteria lurking within samples. As the probes work faster than conventional tests based on fluorescent markers, Nemis believes safety risks could be managed more effectively.
Shlomo Nimrodi, CEO of Ramot, said: “We are excited that our science will be brought to affordable, highly effective technical applications to avoid huge safety challenges throughout the world, potentially saving numerous lives.”
Urs Spiz, chief executive of Biosynth, added: “Today is a great day for the fight against dangerous bacteria. I am very confident that AquaSpark and our easy-to-handle diagnostic kits and solutions will have the potential to replace today’s market standard, fluorescence-based tests, as much as these once replaced color tests.”
